These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23728919)

  • 1. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
    Hoang T; Campbell TC; Zhang C; Kim K; Kolesar JM; Oettel KR; Blank JH; Robinson EG; Ahuja HG; Kirschling RJ; Johnson PH; Huie MS; Wims ME; Larson MM; Hernan HR; Traynor AM
    Invest New Drugs; 2014 Feb; 32(1):195-9. PubMed ID: 23728919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
    Friday BB; Anderson SK; Buckner J; Yu C; Giannini C; Geoffroy F; Schwerkoske J; Mazurczak M; Gross H; Pajon E; Jaeckle K; Galanis E
    Neuro Oncol; 2012 Feb; 14(2):215-21. PubMed ID: 22090453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
    Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
    J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
    Lara PN; Longmate J; Reckamp K; Gitlitz B; Argiris A; Ramalingam S; Belani CP; Mack PC; Lau DH; Koczywas M; Wright JJ; Shepherd FA; Leighl N; Gandara DR
    Clin Lung Cancer; 2011 Jan; 12(1):33-7. PubMed ID: 21273177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
    Jones DR; Moskaluk CA; Gillenwater HH; Petroni GR; Burks SG; Philips J; Rehm PK; Olazagasti J; Kozower BD; Bao Y
    J Thorac Oncol; 2012 Nov; 7(11):1683-90. PubMed ID: 23059775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
    Han JY; Lee SH; Lee GK; Yun T; Lee YJ; Hwang KH; Kim JY; Kim HT
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):475-83. PubMed ID: 25552401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
    Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
    Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
    Deming DA; Ninan J; Bailey HH; Kolesar JM; Eickhoff J; Reid JM; Ames MM; McGovern RM; Alberti D; Marnocha R; Espinoza-Delgado I; Wright J; Wilding G; Schelman WR
    Invest New Drugs; 2014 Apr; 32(2):323-9. PubMed ID: 24114123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
    Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
    Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC
    Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
    Traynor AM; Dubey S; Eickhoff JC; Kolesar JM; Schell K; Huie MS; Groteluschen DL; Marcotte SM; Hallahan CM; Weeks HR; Wilding G; Espinoza-Delgado I; Schiller JH
    J Thorac Oncol; 2009 Apr; 4(4):522-6. PubMed ID: 19347984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
    Lynch TJ; Fenton D; Hirsh V; Bodkin D; Middleman EL; Chiappori A; Halmos B; Favis R; Liu H; Trepicchio WL; Eton O; Shepherd FA
    J Thorac Oncol; 2009 Aug; 4(8):1002-9. PubMed ID: 19633475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
    J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
    Lilenbaum R; Wang X; Gu L; Kirshner J; Lerro K; Vokes E
    J Clin Oncol; 2009 Sep; 27(27):4487-91. PubMed ID: 19704058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
    Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
    Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
    Ramalingam SS; Davies AM; Longmate J; Edelman MJ; Lara PN; Vokes EE; Villalona-Calero M; Gitlitz B; Reckamp K; Salgia R; Wright JJ; Belani CP; Gandara DR
    J Thorac Oncol; 2011 Oct; 6(10):1741-5. PubMed ID: 21716143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.